CATALYST PHARMACEUTICALS

Company snapshot

Catalyst Pharmaceuticals, Inc., (Nasdaq: CPRX) is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients rece

• 3 approved product(s) across US/EU regulatory metadata.
• 23 active pipeline program(s) linked via ClinicalTrials.gov.
• 61 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for CATALYST PHARMACEUTICALS. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for CATALYST PHARMACEUTICALS.

1. Jun 8, 2026 Clinical update

   vigabatrin — Phase 2

2. Jun 8, 2026 Clinical update

   HWK-016, MUCIN-16-targeted ADC — Phase 1

3. Jun 8, 2026 Clinical update

   Dupilumab — Phase 2

4. Jun 8, 2026 Clinical update

   CPP-109 vigabatrin — Phase 2

5. Jun 8, 2026 Clinical update

   Coagulation Factor VIIa variant — Phase 2

View all clinical trial activity →

• What is CATALYST PHARMACEUTICALS?

  Catalyst Pharmaceuticals is a pharma organization headquartered in Coral Gables, USA. It trades on NYSE under ticker CPRX. Primary therapeutic focus areas include Hemophilia A With Inhibitor, Hemophilia A, Hemophilia B, Type2 Diabetes, Emphysema or COPD. NovaPharmaNews links 23 c

• Is CATALYST PHARMACEUTICALS publicly traded?

  Yes. CATALYST PHARMACEUTICALS is listed with ticker CPRX on NYSE per SEC EDGAR records linked on this profile.

• What drugs does CATALYST PHARMACEUTICALS develop or market?

  We link 20 drug profile(s) where CATALYST PHARMACEUTICALS is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/catalyst-pharmaceuticals-inc#company-drugs.

• What are the latest developments for CATALYST PHARMACEUTICALS?

  In the last 12 months our linked public records show 23 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does CATALYST PHARMACEUTICALS focus on?

  CATALYST PHARMACEUTICALS focuses on Hemophilia A With Inhibitor, Hemophilia A, Hemophilia B based on our analysis of their pipeline programs and drug development activities.